Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq exchange until January 15, 2025.
September 19, 2024 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics has been granted an extension by the Nasdaq Hearings Panel to maintain its listing on the Nasdaq until January 15, 2025. This decision provides the company with more time to meet the necessary listing requirements.
The extension granted by Nasdaq is a positive development for Coeptis Therapeutics as it allows the company more time to comply with listing requirements, potentially stabilizing investor confidence and supporting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100